0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > EGFRvIII

EGFRvIII

Brief Information

Name:Epidermal growth factor receptor variant III
Target Synonym:
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:13
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

EGI-HP2H6-Cell-based assay
 EGFRvIII CAR_T

5e5 of anti-EGFRvIII CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human EGFRvIII, His Tag (Cat. No. EGI-HP2H6) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).

EGI-HF2H7-ELISA
 EGFRvIII ELISA

Immobilized Anti-EGFRvIII Antibody , Human IgG1 at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human EGFRvIII Protein, His Tag (Cat. No. EGI-HF2H7) with a linear range of 0.625-5 μg/mL (QC tested).

EGI-H5255-MALS-HPLC
EGFRvIII MALS images

The purity of Human EGFRvIII, Fc Tag (Cat. No. EGI-H5255) is more than 90% and the molecular weight of this protein is around 150-184 kDa verified by SEC-MALS.

Synonym Name

EGFRvIII

Background

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.The type III EGF deletion-mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors; EGFR gene amplification is correlated with the structural rearrangement of the gene. The EGFRvIII gene has an in-frame deletion of 801 base pairs, corresponding to exons 2–7 in the mRNA, resulting in the deletion of amino acids 30-297 in the extracellular domain and the generation of a glycine at the fusion point

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-EGFRvIII-CAR EGFRvIII CAR; Anti-EGFRvIII-CAR Phase 2 Clinical National Cancer Institute, Kite Pharma Glioblastoma; Brain Neoplasms; Gliosarcoma; Glioma Details
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) LXF-821 Phase 1 Clinical University Of Pennsylvania, Novartis Pharma Ag Glioblastoma Details
WSD-0922 WSD-0922; WSD0922 Phase 1 Clinical Wayshine Biopharm International Ltd Glioblastoma; Neoplasms; Astrocytoma; Carcinoma, Non-Small-Cell Lung Details
Etevritamab AMG-596 Phase 1 Clinical Amgen Inc Glioblastoma Details
hEGFRvIII-CD3 Bi-scFv Phase 1 Clinical Duke University Glioblastoma; Glioma Details
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine) Phase 1 Clinical California Institute For Regenerative Medicine, National Cancer Institute Glioblastoma Details
Targeted EGFRvIII autochimeric antigen receptor T cell therapy (DCTY) DCTY0801; DCTY-0801 Phase 1 Clinical Beijing DCTY Biotech Co Ltd Glioblastoma Details
EGFRvIII Targeted Chimeric Antigen Receptor CAR-T Cell Therapy (Chembrain) Phase 1 Clinical Chembrain Ltd Glioblastoma; Glioma Details
GNC-039 GNC-039 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis Details
SNC109 SNC109; SNC-109 Phase 1 Clinical Shanghai Simnova Biotechnology Co Ltd Glioblastoma Details
EGFRvIII-CAR Phase 1 Clinical Duke University Medical Center Glioblastoma Details
RO-7428731 RO-7428731; RG-6156 Phase 1 Clinical F. Hoffmann-La Roche Ltd Glioblastoma Details
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) CPGJ-602; 602; CPGJ602; CPGJ 602 Phase 2 Clinical Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd Colorectal Neoplasms Details
Anti-EGFRvIII-CAR EGFRvIII CAR; Anti-EGFRvIII-CAR Phase 2 Clinical National Cancer Institute, Kite Pharma Glioblastoma; Brain Neoplasms; Gliosarcoma; Glioma Details
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) LXF-821 Phase 1 Clinical University Of Pennsylvania, Novartis Pharma Ag Glioblastoma Details
WSD-0922 WSD-0922; WSD0922 Phase 1 Clinical Wayshine Biopharm International Ltd Glioblastoma; Neoplasms; Astrocytoma; Carcinoma, Non-Small-Cell Lung Details
Etevritamab AMG-596 Phase 1 Clinical Amgen Inc Glioblastoma Details
hEGFRvIII-CD3 Bi-scFv Phase 1 Clinical Duke University Glioblastoma; Glioma Details
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine) Phase 1 Clinical California Institute For Regenerative Medicine, National Cancer Institute Glioblastoma Details
Targeted EGFRvIII autochimeric antigen receptor T cell therapy (DCTY) DCTY0801; DCTY-0801 Phase 1 Clinical Beijing DCTY Biotech Co Ltd Glioblastoma Details
EGFRvIII Targeted Chimeric Antigen Receptor CAR-T Cell Therapy (Chembrain) Phase 1 Clinical Chembrain Ltd Glioblastoma; Glioma Details
GNC-039 GNC-039 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis Details
SNC109 SNC109; SNC-109 Phase 1 Clinical Shanghai Simnova Biotechnology Co Ltd Glioblastoma Details
EGFRvIII-CAR Phase 1 Clinical Duke University Medical Center Glioblastoma Details
RO-7428731 RO-7428731; RG-6156 Phase 1 Clinical F. Hoffmann-La Roche Ltd Glioblastoma Details
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) CPGJ-602; 602; CPGJ602; CPGJ 602 Phase 2 Clinical Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd Colorectal Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken